Abstracts tagged "ANCA"

Abstract Number: 2049 • ACR Convergence 2020
Nasal Bacteria Associated with Disease Activity and ANCA Levels in Granulomatosis with Polyangiitis
Rennie Rhee¹, Jiarui Lu¹, Kyle Bittinger², Antoine Sreih¹, Jung-Jin Lee³, Lisa Mattei³, Brendan Kelly⁴, Peter C. Grayson⁵, Hongzhe Lee⁴, Ronald Collman⁴ and Peter Merkel¹, ¹University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Nasal bacteria have been linked to disease activity in granulomatosis with polyangiitis (GPA) with most studies focused on Staphylococcus aureus. Our previous study identified…
Abstract Number: 0281 • ACR Convergence 2020
ANCA in SLE: Prevalence and Predictor Factors
Reza Mirza¹, Murray Urowitz², Jiandong Su³ and Dafna Gladman⁴, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: SLE is a systemic autoimmune disease notable for the ability to affect nearly every tissue, and is associated with a breadth of auto-antibodies. Anti-neutrophilic…
Abstract Number: 1419 • ACR Convergence 2020
Clinical Disease Might Be Divided into Two Phenotypes in ANCA Associated Vasculitis; Results of a Cluster Analysis
Elif Ediboglu¹, Onay Gercik², Emre Bilgin³, Dilek Solmaz⁴, Irfan Ocal⁵, Arzu Saglam⁶, Zeki Soypacacı², Haluk Cinaklı⁵, Sedat Kiraz³, Ömer Karadağ⁷ and Servet Akar², ¹Izmir Katip Celebi University, Izmir, Izmir, Turkey, ²Izmir Katip Celebi University, Izmir, Turkey, ³Hacettepe University, Ankara, Turkey, ⁴Izmir Katip Celebi University, Department of Internal Medicine, Division of Rheumatology, Izmir, TURKEY, Izmir, Turkey, ⁵Izmir Katip Celebi University, Izmir, ⁶Hacettepe University, Ankara, ⁷Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara,, Ankara, Turkey
Background/Purpose: One of the controversial matters in ANCA associated vasculitis is the definition of disease based on clinical characteristics since there is a remarkable overlap…
Abstract Number: 1420 • ACR Convergence 2020
Characterization of ANCA-Associated Vasculitis Among African American Patients
Sehris Khawaja¹, Saloni Godbole¹, Maryann Kimoto², Virginia Steen³ and Kaitlin Quinn⁴, ¹Georgetown University, Washington, DC, ²UCLA, Los Angeles, CA, ³Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁴National Institutes of Health, Washington, DC
Background/Purpose: ANCA-associated vasculitis (AAV) comprises a group of disorders characterized by inflammation of small and medium-sized arteries. Prevalence and phenotype of these diseases appear to…
Abstract Number: 1421 • ACR Convergence 2020
Clinical Features, Disease Activity and Prognosis of ANCA-Associated Vasculitis in US African Americans
Luis Palomino¹, Angelo Gaffo², Sebastian Sattui³ and Dongmei Sun², ¹University of Alabama at Birmingham Hospital, Birmingham, AL ²University of Alabama at Birmingham, Birmingham, AL, ³Hospital for Special Surgery, New York, NY
Background/Purpose: ANCA-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Microscopic Polyangiitis (MPA), affect mostly Caucasians of European descent. Clinical…
Abstract Number: 1430 • ACR Convergence 2020
The Role of Lung Biopsy in Pediatric ANCA-associated Vasculitis
Edouard Sayad¹, Tiphanie Vogel¹, David Moreno McNeill¹, Nahir Cortes-Santiago¹, David Spielberg¹, Kalyani Patel¹ and Manuel Silva Carmona¹, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Anca-associated vasculitis (AAV) is characterized by vascular inflammation in multiple organs. The diagnosis can be made clinically using a number of different criteria. The…
Abstract Number: 1432 • ACR Convergence 2020
Thyroid Disease in Patients with ANCA-Associated Vasculitis
Tanaz Kermani¹, David Cuthbertson², Simon Carette³, Nader Khalidi⁴, Curry L. Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih¹³, Kenneth Warrington¹² and Peter Merkel¹³, ¹University of California Los Angeles, West Hills, CA, ²University of South Florida, Tampa, ³Division of Rheumatology, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah, Salt Lake City, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, ⁸Brigham and Women's, Boston, ⁹University of Pittsburgh, Denver, CO, ¹⁰Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Prior studies have found increased prevalence of thyroid disease in patients with ANCA-associated vasculitis (AAV), especially positive myeloperoxidase (MPO)-ANCA, but a majority of the…
Abstract Number: 1433 • ACR Convergence 2020
Thyroid Disease in ANCA-associated Vasculitis. a Population-based Study
Anna Wilding¹, Rona Smith², David Jayne³, Mårten Segelmark⁴ and Aladdin Mohammad⁵, ¹Lund University, Staffanstorp, Sweden, ²University of Cambridge, Cambridge, United Kingdom, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁴Lund University, Lund, ⁵Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: A higher incidence of thyroid disease has been seen in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We aim to assess the incidence…
Abstract Number: 1435 • ACR Convergence 2020
Prognostic Factors for Mononeuritis Multiplex Associated with ANCA-associated Vasculitis
Yutaro Hayashi¹, Satoshi Hama², Keisuke Izumi², Mari Ushikubo¹, Misako Konishi³, Yutaka Okano⁴ and Hisaji Ohshima², ¹Tokyo medical center, Tokyo, Japan, ²Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, ³Tokyo medical center, toukyouto Meguroku, Japan, ⁴Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan
Background/Purpose: ANCA-associated vasculitis (AAV) sometimes presents mononeuritis multiplex which worsens the prognosis and activity of daily living in patients. This study aimed to determine theprognostic factorsand…
Abstract Number: 068 • 2020 Pediatric Rheumatology Symposium
Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus
Linda Wagner-Weiner ¹, Vidya Sivaraman ², Karen James ³, Eric Yen ⁴, Kathleen O'Neil ⁵, Dana Gerstbacher ⁶, Ann Marie Szymanski⁷, Kimberly Morishita ⁸ and David Cabral ⁹ for the CARRA investigators, ¹University of Chicago, Chicago, Illinois, ²Division of Rheumatology, Nationwide Children's Hospital, Bexley, ³University of Utah, 84113, Utah, ⁴UCLA, Los Angeles, California, ⁵University of Indiana School of Medicine, Indianapolis, Indiana, ⁶Stanford University School of Medicine, Palo Alto, California, ⁷Tampa, Florida, ⁸University of British Columbia - Vancouver, Vancouver, British Columbia, Canada, ⁹BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
Background/Purpose: Randomized trials for pediatric ANCA-associated vasculitis (ped-AAV) have not been feasible because of its rarity, therefore adult treatment strategies are usually adapted for children.…
Abstract Number: 102 • 2020 Pediatric Rheumatology Symposium
Implications of Positive Tests for ANCA in a Pediatric Population
Karen James¹, Peter Merkel ² and Aimee Hersh ³, ¹University of Utah, 84113, Utah, ²University of Pennsylvania, Philadelphia, ³University of Utah Primary Children's Hospital, Salt Lake City
Background/Purpose: Testing for ANCA, particularly performed by ELISA (anti-MPO/PR3) is highly sensitive and specific for ANCA-associated vasculitis (AAV). However ANCA testing may be used in…
Abstract Number: 1675 • 2019 ACR/ARP Annual Meeting
A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis
Liqin Wang¹, Eli Miloslavsky ², John Stone ³, Hyon K. Choi ⁴, Li Zhou ⁵ and Zachary Wallace ², ¹Brigham and Women's Hospital, Boston, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with end-organ damage, complications of treatment, and excess death. Retrospective studies on the clinical course of AAV, including the…
Abstract Number: 2634 • 2019 ACR/ARP Annual Meeting
ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients
Laura van Dam¹, Ebru Dirikgil ², Edwin Bredewold ², Argho Ray ², Ton Rabelink ², Cees van Kooten ² and Onno Teng ², ¹LUMC, Leiden, Zuid-Holland, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Recent studies have demonstrated that in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with successful remission-induction (RI) after cyclophosphamide (CYC), maintenance treatment with…
Abstract Number: 1678 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in ANCA Associated Vasculitis: A Single Center Retrospective Analysis
Haidy Adel Youssef¹ and Mehrnaz Hojjati ², ¹Riverside Community Hospital/ UCR School of Medicine Internal Medicine Residency Program, Corona, CA, ²Department of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: ANCA associated vasculitis patients have a wide spectrum of pulmonary involvement in the form nodular disease (especially peri-bronchial nodules), cavitating lesions, diffuse alveolar hemorrhage and less…
Abstract Number: 2637 • 2019 ACR/ARP Annual Meeting
Urine Complement Ba Levels During Flares of Renal Disease in Patients with ANCA-Associated Vasculitis
Salem Almaani¹, Christopher Toy ², Anna Levesque ², Lynn Fussner ¹, Alexa Meara ¹, Lianbo Yu ¹, David Cuthbertson ³, Simon Carette ⁴, Nader A. Khalidi ⁵, Curry L. Koening ⁶, Carol Langford ⁷, Carol A. McAlear ⁸, Larry Moreland ⁹, Christian Pagnoux ¹⁰, Philip Seo ¹¹, Antoine Sreih ¹², Steven Ytterberg ¹³, Paul Monach ¹⁴, Peter Merkel ¹², Brad Rovin ¹ and Dan Birmingham ¹⁵, ¹The Ohio State University Medical Center, Columbus, OH, ²Ohio State University, Columbus, OH, ³University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Utah Hospital, Salt Lake City, UT, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ⁹University of Pittsburgh, PITTSBURGH, PA, ¹⁰Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ¹¹Johns Hopkins Medicine, Baltimore, MD, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Brigham and Women's Hospital, Boston, MA, ¹⁵The Ohio State University Medical Center, Columbus
Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV). Change in markers of complement activation within patients have not…

« Previous Page
1
…
4
5
6
7
8
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].